information are encouraged. Your comments should address one or more of the following four points:

—Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;
—Evaluate the accuracy of the agencies estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;
—Enhance the quality, utility, and clarity of the information to be collected; and
—Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submission of responses.

Overview of this information collection:

(1) Type of Information Collection: Extension, without change, of a currently approved collection.
(2) Title of the Form/Collection: Annuity Broker Qualification Declaration Form.
(3) Agency form number, if any, and the applicable component of the Department of Justice sponsoring the collection: Department of Justice, Civil Division.
(4) Affected public who will be asked or required to respond, as well as a brief abstract: Primary: Individuals. This declaration is to be submitted annually to determine whether a broker meets the qualifications to be listed as an annuity broker pursuant to Section 11015(b) of Public Law 107-273.
(5) An estimate of the total number of respondents and the amount of time estimated for an average respondent to respond: It is estimated that 400 respondents will complete the form annually within approximately 1 hour.
(6) An estimate of the total public burden (in hours) associated with the collection: There are an estimated 400 total annual burden hours associated with this collection.

If additional information is required contact: Lynn Bryant, Department Clearance Officer, United States Department of Justice, Justice Management Division, Policy and Planning Staff, Patrick Henry Building, Suite 1600, 601 D Street NW., Washington, DC 20530.

Dated: August 1, 2006.

Lynn Bryant,
Department Clearance Officer, Department of Justice.

[FR Doc. 06-6697 Filed 8-3-06; 8:45 am]
BILLING CODE 4410-12-M

DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–273N]
Solicitation of Information on the Use of Tryptamine-Related Compounds

AGENCY: Drug Enforcement Administration (DEA), Justice.

ACTION: Notice of request for information.

SUMMARY: The DEA is soliciting information on substances that are related in chemical structure to tryptamine (see SUPPLEMENTARY INFORMATION: The Controlled Substances Act (CSA), in Title 21 of the United States Code (U.S.C. 812(c) Schedule I (Title 21 of the Code of Federal Regulations (CFR 1308.11(d)), lists certain tryptamines as Schedule I controlled substances. Some tryptamines that are not controlled under the CSA produce central nervous system effects that are similar to tryptamines that are controlled under the CSA. DEA is requesting information to help determine the impact on business if these substances were to be placed under control in the CSA.

DATES: Written comments must be postmarked, and electronic comments must be sent, on or before October 3, 2006.

ADDRESSES: To ensure proper handling of comments, please reference “Docket No. DEA–273N” on all written and electronic correspondence. Written comments being sent via regular mail should be sent to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Attention: DEA Federal Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria, VA 22301. Comments may be directly sent to DEA electronically by sending an electronic message to dea.diversion.policy@usdoj.gov. Comments may also be sent electronically through http://www.regulations.gov using the electronic comment form provided on that site. An electronic copy of this document is also available at the http://www.regulations.gov Web site. DEA will accept attachments to electronic comments in Microsoft Word, WordPerfect, Adobe PDF, or Excel file formats only. DEA will not accept any file format other than those specifically listed here.

FOR FURTHER INFORMATION CONTACT: Christine A. Sannerud, Ph.D., Chief, Drug and Chemical Evaluation Section, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537; Telephone: (202) 307–7183.

SUPPLEMENTARY INFORMATION:
Tryptamine is a compound in which the chemical structure can be described as indole substituted at the three position with an 2-aminoethyl chain. Although tryptamine itself is not a controlled substance, its chemical structure constitutes the skeletal makeup of the tryptamines listed in Schedule I of the CSA, which are classified as hallucinogenic substances.

Tryptamine is sometimes substituted on the indole ring or the 2-aminoethyl chain or both with various substituents. Title 21 CFR 1308.11(d) lists specific substituted tryptamines in Schedule I. Also included in Schedule I are the salts, isomers, and salts of isomers of the listed tryptamines. The term isomer, as used in this section, means the optical, geometric, and positional isomers.

Individuals have published detailed methods of synthesis for substituted tryptamines and have reported pharmacological effects based on user experiences. Law enforcement personnel encounter such tryptamines, but because they are substituted differently than those listed or described in the CSA, they are not subject to direct control in Schedule I. However, some of these substances can be treated as Schedule I controlled substance analogues if intended for human consumption (21 U.S.C. 802(32); § 813). DEA is soliciting information on (1) the commercial uses for tryptamines, (2) activities involving research and development, (3) tryptamines as intermediates or analytical standards, (4) import and domestic sources for tryptamines, and (5) any planned or anticipated uses for tryptamines. DEA invites interested persons to provide any information on the uses of tryptamines in industry, academia, research and development, or other applications. Both qualitative and quantitative information is sought.

Although information is requested for all tryptamine substances regardless of substitutions, DEA is particularly interested in tryptamines that meet one
or more of the following conditions: (a) Has a secondary or tertiary amine formed by the substitution on the nitrogen atom of the 2-aminoethyl chain by various alkyl groups, whether in chain or ring form (for example, N-alkyltryptamine, N,N-dialkyltryptamine, N,N-tetramethylenetryptamine), (b) has an alkyl substitution on the alpha position of the 2-aminoethyl chain, and/or (c) has substituents on the indole ring system, including, but not restricted to, various alkyl chains, halogens, hydroxyl, alkoxy, acetyl, or alkylthio groups, at one or more positions except the one (indenone nitrogen) position. DEA is especially interested in learning of the uses of the following tryptamines.

- 2-alpha-dimethyltryptamine
- 4-acetoxy-N,N-diethyltryptamine
- 5-methoxy-N,N-diallyltryptamine
- 4-acetoxy-N,N-dimethyltryptamine
- 5-methoxy-N,N-diallyltryptamine
- 5-methoxy-N,N-diallyltryptamine
- 4-methoxy-N,N-dimethyltryptamine
- 5-methoxy-N,N-dimethyltryptamine
- 4-methoxy-N,N-dimethyltryptamine
- 5-methoxy-N,N-diethyltryptamine
- 5-methoxy-N,N-dimethyltryptamine
- 5-methoxy-N,N-diethyltryptamine
- 5-methoxy-N,N-diethyltryptamine
- 5-methoxy-N,N-diethyltryptamine
- 5-methoxy-N,N-diethyltryptamine
- 5-methoxy-N,N-diethyltryptamine
- 5-methoxy-N,N-diethyltryptamine
- 5-methoxy-N,N-diethyltryptamine
- 5-methoxy-N,N-diethyltryptamine

Such information may be submitted to the Drug and Chemical Evaluation Section and is requested by October 3, 2006. Information designated as confidential or proprietary will be treated accordingly. Confidential business information is protected from disclosure under Exemption 4 of the Freedom of Information Act, 5 U.S.C. 552(b)(4)(FOIA) and the Department of Justice procedures set forth in 28 CFR 16.8.


Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control.

[FR Doc E6–12599 Filed 8–3–06; 8:45 am]
BILLING CODE 4410–09–P

DEPARTMENT OF LABOR
Employment and Training Administration

[TA–W–58,819]

Bentwood Furniture, Inc., Grants Pass, OR; Affirmative Determinations for Worker Adjustment Assistance and Alternative Trade Adjustment Assistance; Correction

This notice rescinds the notice of certification of eligibility to apply for Alternative Trade Adjustment Assistance applicable to TA–W–58,819, which was published in the Federal Register on April 13, 2006 (71 FR 17,206).

This rescinds the certification of eligibility for workers of TA–W–58,819, to apply for Alternative Trade Adjustment Assistance and confirms eligibility to apply for Worker Adjustment Assistance as identified on page 19209 in the first column, the sixteenth TA–W–number listed.

The Department appropriately published in the Federal Register April 13, 2006, page 19210, under the notice of Negative Determinations for Alternative Trade Adjustment Assistance, the denial of eligibility applicable to workers of TA–W–58,819.

The notice appears on page 19210 in the third column, the fifth TA–W–number listed.

Signed in Washington, DC, this 28th day of July 2006.

Erica R. Cantor,
Director, Division of Trade Adjustment Assistance.

[FR Doc E6–12619 Filed 8–3–06; 8:45 am]
BILLING CODE 4510–30–P

DEPARTMENT OF LABOR
Employment and Training Administration

[TA–W–58,759]

Buckingham Galleries, New Hartford, CT; Affirmative Determinations for Worker Adjustment Assistance and Alternative Trade Adjustment Assistance; Correction

This notice rescinds the notice of certification of eligibility to apply for Alternative Trade Adjustment...